Close menu




September 8th, 2021 | 12:28 CEST

PuriflOH, Bayer, Philips - Innovations as yield drivers

  • Investments
Photo credits: pixabay.com

Innovations enrich our everyday lives in many ways. The following companies have developed innovative solutions for health and climate in the broadest sense that help remedy important problems. The focus here is on water, a scarce resource, and air purification, which in times of Corona plays an increasingly important role. Which Company has the best opportunities?

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: PURIFLOH LTD | AU0000010548 , BAYER AG NA O.N. | DE000BAY0017 , KONINKL. PHILIPS EO -_20 | NL0000009538

Table of contents:


    PURIFLOH LIMITED - Innovator from Australia with worldwide patents

    Founded in Australia with a US office in Detroit, PuriflOH has developed innovative and globally patented technology for cleaning air, water and surfaces in residential, commercial and industrial settings. According to the Company, PuriflOH has developed the first and only single solution to remove biological and chemical contaminants from the air through a two-step process.

    IP licensing and partnership opportunities with air purification equipment manufacturers for residential, commercial and industrial applications are currently being explored. PuriflOH solutions are easily expandable and, therefore, scalable. In the past, the Company undertook significant research activities to develop the Free Radical Generator (FRG) technology. Now, the Company is leveraging the expertise of Somnio Group for further development.

    Most recently, the Australians announced that commercialization activities would resume in Australia with two new products. These are the Air Conditioning Environmental Remediation Treatment (ACERT) and the Whole of Room Air Purifier (WRAP). In addition, PuriflOH built relationships with Aspen Medical, a healthcare solutions company, and Osmoflo, a water treatment company. Both partners play an important role in the future commercialization of the products.

    The Company is still in the red, but this is characteristic of the relatively early stage. However, the loss was significantly reduced in the fiscal year. In addition, the Company secured an AUD 1 million financing facility from its major shareholder Dilato. Currently, PuriflOH is valued at AUD 53 million. As the products are commercialized, operating income will quickly materialize. Technology-savvy investors should put the shares on their watchlist.

    BAYER AG - Turnaround in sight?

    Climate change is again causing problems for agriculture this year. According to the recently published harvest report by the German Federal Ministry of Agriculture and statements by the farmers' association, heavy rain and hail will lead to a 2.7% decline in the grain harvest this year. Compared to the years 2015 to 2020, this is even a decrease of 4.8%. While too much water has caused problems in this country, water scarcity is a major problem globally. 70% of the world's water is consumed by agriculture. By the end of the decade, demand will already exceed supply. Water is thus becoming a crucial bottleneck factor.

    Even if Bayer is more present in the media through its pharmaceuticals business and its cooperation with the Corona vaccine manufacturer CureVac, whose vaccine has not yet reached the marketing stage due to a lack of vaccine protection, Bayer's strong second pillar is agricultural chemistry. Here, the DAX-listed Company is focusing on targeted research activities to enable water-efficient agriculture. It also develops and markets products and technologies for improved wastewater treatment. Disappointing half-year figures and the lawsuits pending for some time in the USA in connection with carcinogenic fertilizers from the acquired competitor Monsanto led to a significant underperformance of around 10% against the DAX this year. 2021 will undoubtedly be a challenging year for the Group, but analysts expect things to pick up again significantly in 2022. The 2022 P/E ratio is 10, and the stock is currently interesting for anti-cyclical investors.

    KONINKLIJKE PHILIPS NV - Established player with industry-standard valuation

    Koninklijke Philips NV is a leading healthcare technology company with a wide range of products from healthy living and prevention to diagnosis, treatment and home care. The Group uses advanced technologies and sound clinical and consumer insights to provide integrated solutions. The Dutch-based Company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, and consumer health and home care. In Corona times, the air purifier sector has taken on greater importance. The Group is currently valued at around EUR 37 billion, 2 times projected 2022 sales and a 2022 P/E of 24.


    The featured stocks focus on climate, health and water as a resource. In doing so, all companies focus on different areas. Bayer is one of the leading players in agricultural chemicals. After a year of losses, next year should see a return to gratifying profits - this makes the shares interesting. Anyone who wants to invest in a young technology company that offers a range of innovative solutions should take a closer look at the PuriflOH share.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 29th, 2022 | 13:32 CET

    Nvidia, Meta Materials, SFC Energy - Strong signs

    • Technology
    • Investments
    • nanotechnology

    After turbulent months on the technology stock markets with high markdowns, a bottoming out is taking place across the board. While many companies are reporting better-than-expected figures, investors are also buying oversold companies whose quarterly figures were below analysts' consensus. Due to the still high fluctuation range, high trading profits can be expected.

    Read

    Commented by Stefan Feulner on November 28th, 2022 | 10:41 CET

    SynBiotic SE, Cardiol Therapeutics, Canopy Growth - Like hitting the jackpot

    • Cannabis
    • Investments

    The final draft of the German government's key issues paper on the legalization of cannabis in Germany is ready, and final approval is likely to be a mere formality. For the companies concerned, this is equivalent to winning the lottery. The global cannabis market is expected to grow by 13.9% annually to USD 64.91 billion between 2022 and 2027. However, these profit increases have yet to reach the stock market. Some companies, for example, are trading below cash, while others lost more than 90% of their value in the correction that has been underway since 2019.

    Read

    Commented by Stefan Feulner on November 25th, 2022 | 23:16 CET

    Viromed Medical AG, Encavis AG, K+S - The foundation is laid

    • Covid19
    • Investments

    For weeks now, the most important stock markets around the globe have been on an upward trend. What was initially only declared as a countermovement in the overriding downward movement could now be the start of a more pronounced year-end rally. While indices such as the DAX and the Dow Jones have already managed to break out of the downtrends they have been following since the start of the Ukraine war, smaller stocks, in particular, still offer considerable catch-up potential.

    Read